March 4, 2014

IAVI, the International AIDS Vaccine Initiative, congratulates the researchers behind a landmark study mapping the evolution of a broadly neutralizing antibody (bNAb) against HIV. The study - by scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health; Columbia University; the Centre for the AIDS Programme of Research in South Africa (CAPRISA); and South Africa’s National Institute for Communicable Diseases, and published in Nature - traces the interplay between HIV and the antibody that led to maturation to its final, highly potent form.
 
“This study provides important clues to vaccine design,” said Wayne C. Koff, IAVI Chief Scientific Officer. “bNAbs bind to the ‘vulnerable, conserved’ sites on the human immunodeficiency virus. Knowing how they evolve naturally gives us all greater potential for developing a vaccine that can do the same thing.”

Media Contacts

Africa

Ethel Makila
+254 71 904 3142
EMakila@iavi.org

 

Europe

Hester Kuipers
+31 20 521 0343
HKuipers@iavi.org 

 

Global

Anita Kawatra
+1 212 847 1055
AKawatra@iavi.org 

 

India

Saif ul Hadi
+91 11 4737 6032
SulHadi@iavi.org 

 

United States

Rose Catlos
+1 212 847 1049
RCatlos@iavi.org